**Pint Size Pharmacotherapy: Principles of Psychotropic Use in Pediatrics**

**Video Conference – February 24, 2021**

**1:00 to 3:00 PM**

|  |
| --- |
| **Presenter Bio** |
| **Hannah Goulding, PharmD**Clinical PharmacistUPMC Western Psychiatric HospitalPittsburgh, PAHannah Goulding completed her Bachelor of Science in Pharmaceutical Sciences and Doctor of Pharmacy form the University of North Carolina Chapel Hill. She completed her PGY1 pharmacy residency at UPMC Western Psychiatric Hospital and currently works on the Center for Autism and Developmental Disabilities unit and outpatient consulting for the psychiatry residents’ child and adolescent clinics. **Andreea Temelie, PharmD**PGY2 Psychiatric Pharmacy ResidentUPMC Western Psychiatric HospitalPittsburgh, PAAndreea Temelie completed her Bachelor of Science in psychology from the University of Michigan and a Doctor of Pharmacy with a leadership emphasis and interprofessional mental health focus from the University of Minnesota. She completed her PGY1 pharmacy residency at UPMC Western Psychiatric Hospital. Her professional interests include child/adolescent psychiatry, psychosis, mood disorders, transitions of care, and underserved care.  |
| **Name and Narrative Description of your Presentation** |
| **Pint Size Pharmacotherapy: Principles of Psychotropic Use in Pediatrics (Introductory)**This presentation will provide an overview of childhood onset mental health conditions and an introductory review of current treatment approaches including both FDA-approved and off-label use of pharmacotherapy. We will also review complementary and alternative medicines that may be used in this patient population. The conditions that will be covered throughout this presentation include attention deficit hyperactive disorder, anxiety, depression, early onset schizophrenia, bipolar disorder, autism spectrum disorder, conduct disorder, oppositional defiant disorder, reactive attachment disorder, disinhibited social engagement disorder, and disruptive mood dysregulation disorder. |
| **Three (3) learning objectives** |
| By the completion of this session, participants should be able to: 1. Identify principles of pediatric pharmacotherapy for common mental health disorders
2. Discuss FDA approved psychotropic medications in pediatrics and how this applies to clinical practice
3. Recognize the different complementary and alternative medicines appropriate for psychiatric use
 |
| **Three (3) current (within the past 10 years) *peer-reviewed* publications** **that support the evidence base for the content of your presentation** |
| 1. Subcommittee on children and adolescents with attention-deficit/hyperactive disorder. (2019) ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatrics.* 144 (4), e21092528
2. Accordino, R.E., Kidd C., Politte L.C., et al. (2016) Psychopharmacological interventions in autism spectrum discorder. *Expert Opinion on Pharmacotherapy.* 17(7),937-952.
3. Ravindran, A. V., Balneaves, L. G., Faulkner, G., et al. CANMAT Depression Work Group (2016). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments. *Can J Psychiatry.* *61*(9), 576–587.
 |